Table 1 Ongoing trials evaluating the role of sentinel node biopsy in breast cancer
From: Current status of sentinel lymph node biopsy in solid malignancies
Start date | Sample size | Design | |
|---|---|---|---|
Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) | 2000 | 1260 | Randomise to: ALND or sampling vs. SN biopsy |
After Mapping of the Axilla: Radiotherapy or Surgery (AMAROS) | 2001 | 3485 | If SN positive randomise to: ALND vs. RT |
German Clinical Interdisciplinary Sentinel Study (KiSS) | 2000 | 1912 | If SN negative randomise to: ALND vs. no ALND |
French Randomised Sentinel Node Study (Fransenod) | NA* | 446 | SN biopsy patients randomised to peritumoural injection vs. periareolar injection |
International Breast Cancer Study Group Trial (IBCSG 23-01) | 2001 | 1960 | If SN positive for micrometastases(IHC), randomise to: ALND vs. no ALND |
American College of Surgeons Oncology Group (ACOSOG-Z0010) | 1999 | 5300 | IHC positive SN patients(H&E negative) observed to determine prognostic significance; bone marrow also assayed for micrometastasis to determine incidence and significance |
American College of Surgeons Oncology Group (ACOSOG-Z0011) | 1999 | 1900 | If SN positive(H&E) randomise to completion ALND vs. observation |
National Surgical Adjuvant Breast and Bowel Project(NSABP-B-32) | 1999 | 4500 | If SN negative randomise to: completion ALND vs. no additional axillary treatment |
Royal Australasian College of Surgeons Sentinel lymph Node biopsy versus Axillary Clearance (RACS SNAC) | 2001 | 1000 | SN negative patients randomised to completion ALND vs. no additional axillary treatment |